Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have been given an average recommendation of “Moderate Buy” by the twelve analysts that are currently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $39.0714.

Several research firms have issued reports on GMAB. Wells Fargo & Company began coverage on shares of Genmab A/S in a research note on Monday, March 2nd. They issued an “overweight” rating and a $40.00 target price on the stock. Jefferies Financial Group began coverage on shares of Genmab A/S in a research note on Tuesday, February 17th. They issued a “buy” rating and a $41.50 target price on the stock. Wall Street Zen cut shares of Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Wolfe Research began coverage on shares of Genmab A/S in a research report on Friday, March 27th. They set an “outperform” rating and a $32.00 price objective on the stock. Finally, Truist Financial upgraded shares of Genmab A/S to a “strong-buy” rating in a research report on Monday, April 27th.

Genmab A/S Stock Performance

NASDAQ GMAB opened at $26.39 on Monday. Genmab A/S has a 1 year low of $18.89 and a 1 year high of $35.43. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.02 and a quick ratio of 2.01. The stock has a market capitalization of $16.45 billion, a PE ratio of 19.99, a P/E/G ratio of 1.20 and a beta of 0.86. The company’s 50 day simple moving average is $27.32 and its two-hundred day simple moving average is $29.91.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Thursday, May 7th. The company reported $0.15 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.15. Genmab A/S had a net margin of 21.05% and a return on equity of 15.37%. The business had revenue of $896.00 million for the quarter, compared to analysts’ expectations of $905.77 million. Analysts predict that Genmab A/S will post 1.19 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

Several institutional investors and hedge funds have recently made changes to their positions in GMAB. EverSource Wealth Advisors LLC raised its position in shares of Genmab A/S by 124.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock valued at $44,000 after buying an additional 1,174 shares in the last quarter. Sei Investments Co. raised its position in shares of Genmab A/S by 4.2% during the 2nd quarter. Sei Investments Co. now owns 62,111 shares of the company’s stock valued at $1,283,000 after buying an additional 2,496 shares in the last quarter. Squarepoint Ops LLC raised its position in shares of Genmab A/S by 636.3% during the 2nd quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock valued at $1,947,000 after buying an additional 81,434 shares in the last quarter. Quantinno Capital Management LP raised its position in shares of Genmab A/S by 64.9% during the 2nd quarter. Quantinno Capital Management LP now owns 158,132 shares of the company’s stock valued at $3,267,000 after buying an additional 62,226 shares in the last quarter. Finally, Raymond James Financial Inc. raised its position in shares of Genmab A/S by 48.1% during the 2nd quarter. Raymond James Financial Inc. now owns 31,146 shares of the company’s stock valued at $643,000 after buying an additional 10,113 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.